HIV env antibodies

Details HIV env antibodies HIV env antibodies

2006-05-09

2006-05-09

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S160100, C424S183100, C435S005000, C435S007100, C435S070210, C435S326000, C435S339000, C435S339100, C435S346000, C530S388100, C530S388300, C530S388350

Reexamination Certificate

active

07041293

ABSTRACT:
The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.

REFERENCES:
patent: 4361647 (1982-11-01), Remington et al.
patent: 4474893 (1984-10-01), Reading
patent: 4725669 (1988-02-01), Essex et al.
patent: 5166050 (1992-11-01), Shriver et al.
patent: 33320/89 (1989-11-01), None
patent: 65235/90 (1991-04-01), None
patent: 187041 (1986-09-01), None
patent: 0 339 504 (1988-11-01), None
patent: 0 315 459 (1989-10-01), None
patent: 0 335 635 (1989-10-01), None
patent: 120284/1989 (1989-05-01), None
patent: WO 89/12095 (1989-12-01), None
patent: WO 90/02196 (1990-03-01), None
patent: WO 91/13906 (1991-09-01), None
patent: WO 93/20104 (1993-10-01), None
Berman et al. PNAS. 1988; 85 (14): 5200-4, provide in the IDS.
Desrosiers Nature Medicine. Mar., 2004; 10 (3): 221-223.
Lasky et al. Cell. 1987; 50: 975-985, provided in the IDS.
Berman et al. Journal of Virology. 1989; 63 (8): 3489-3498, provided in the IDS.
Matsushita et al. Journal of Virology. 1988; 62 (6): 2107-2114, provided in the IDS.
Dowbenko et al. Journal of Virology. 1988; 62 (12): 4703-4711.
Javaherian et al. PNAS. 1989; 86: 6768-6772, provided in the IDS.
Allan et al., “Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III”Science228 (4703):1091-1094 (May 1985).
Anderson et al., “Effect of Dose and Immunization Schedule on Immune Response of Baboons to Recombinant Glycoprotein 120 of HIV-1,”Jour. of Infectious Diseases, 160(6):960-969 (1989).
Arthur et al., “Challenge of Chimpanzees (Pan troglodytes) Immunized with Human Immunodeficiency Virus Envelope Glycoprotein gp120,”Jour. of Virology63(12):5046-5053 (1989).
Barin et al., “Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients,”Science228:1094-1096 (1985).
Barrett et al., “Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gp 160 and Analysis of Its Immunogenicity,”AIDS Research and Human Retroviruses5(2):159-171 (1989).
Berman et al., “Expression and Immunogenicity of the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, gp160”Jour. of Virology63(8):3489-3498 (1989).
Berman et al., “Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120”Proc. Natl. Acad. Sci. USA85:5200-5204 (1988).
Berman et al., “Protection from Genital Herpes Simplex Virus Type 2 Infection by Vaccination with Cloned Type 1 Glycoprotein D,”Science227:1490-1492 (1985).
Berman et al., “Protection of Chimpanzees From Infection by HIV-1 After Vaccination With Recombinant Glycoprotein gp120 but not gp160,”Nature345:622-625 (1990).
Chakrabarti et al., “Expression of the HTLV-III envelope Gene by a Recombinant Vaccinia Virus,”Nature320:535-540 (1986).
Clements et al., “The V3 Loops of the HIV-1 and HIV-2 Surface Glycoproteins Contain Proteolytic Cleavage Sites; A Possible Function in Viral Fusion”AIDS Research and Human Retroviruses7:3-16 (1991).
Desrosiers et al., “Vaccine protection against simian immunodeficiency virus infection,”Proc. Natl. Acad. Sci. USA86:6353-6357 (1989).
Fahey et al., “Status of immune-based therapies in HIV infection and AIDS,”Clin. exp. Immunol.88:1-5 (1992).
Fauci et al., “Development and Evaluation of a Vaccine for Human Immunodeficiency Virus (HIV) Infection”Annals of Internal Med.110(5):373-385 (1989).
Fox, J.L., “No Winners Against AIDS,”Bio/Technology12:128 (Feb. 1994).
Homsy et al., “The Fc and Not CD4 Receptor Mediates Antibody Enhancement of HIV Infection in Human Cells,”Science244:1357-1360 (1989).
Hu et al., “Effect of Immunization With a Vaccinia-HIV env Recombinant on HIV Infection of Chimpanzees,”Nature328:721-723 (1987).
Hu et al., “Expression of AIDS virus envelope gene in recombinant vaccinia viruses,”Nature320:537-540 (1986).
Jahaverian et al., “Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein,”Proc. Natl. Acad. Sci. USA86:6768-6772 (1989).
Kitchen et al., “Aetiology of AIDS—antibodies to human T-cell leukaemia virus (type III) in haemophiliacs,”Nature312:367-369 (1984).
Krust et al., “Characterization of a monoclonal antibody specific for the HIV-1 precursor glycoprotein,”AIDS2:17-24 (1988).
Lasky, Laurence A., “Current Status of the Development of an AIDS Vaccine,”Crit. Revs. in Immunology9(3):153-172 (1989).
Lasky et al., “Delineation of a Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical for Interaction with the CD4 Receptor,”Cell50:975-985 (1987).
Lasky et al., “Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein,”Science233:209-212 (1986).
Letvin et al., “AIDS-like Disease in Macaque Monkeys Induced By Simian Immunodeficiency Virus: A Vaccine Trial,”Vaccines87:209-213 (1987).
Looney et al., “Type-Restricted Neutralization of Molecular Clones of Human Immunodeficiency Virus,”Science241:357-359 (1988).
Matsushita et al., “Characterization of a Human Immunodeficiency Virus Neutralizing Monoclonal Antibody and Mapping of the Neutralizing Epitope,”Jour. of Virology62(6):2107-2114 (1988).
Modrow et al., “Computer-Assisted Analysis of Envelope Protein Sequences of Seven Human Immunodeficiency Virus Isolates: Prediction of Antigenic Epitopes in Conserved and Variable Regions,”Jour. of Virology61(2):570-578 (1987).
Murphy-Corb et al., “A Formalin-Inactivated Whole SIV Vaccine Confers Protection in Macaques,”Science2:1293-1297 (1989).
Newmark, Peter, “Receding Hopes of AIDS vaccines,”Nature333:699 (1988).
Palker et al., “Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides,”Proc. Natl. Acad. Sci. USA85:1932-1936 (1988).
Prince et al., “Failure of a Human Immunodeficiency Virus (HIV) Immune Globulin to Protect Chimpanzees Against Experimental Challenge With HIV,”Proc. Natl. Acad. Sci. USA85:6944-6948 (1988).
Robey et al., “Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody,”Porc. Natl. Acad. Sci.83:7023-7027 (1986).
Robey, W.G. et al., “Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients,”Science 228(4699):593-595 (May 3, 1985).
Robinson, Jr. et al., “Antibody-Dependent Enhancement of Human Immunodeficiency Virus Type 1 Infection,”The Lancet790-794 (1988).
Robinson, Jr. et al., “Human Monoclonal Antibodies to the Human Immunodeficiency Virus Type 1 (HIV-1) Transmembrane Glycoprotein gp41 Enhance HIV-1 Infection in vitro,”Proc. Natl. Acad. Sci. USA87:3185-3189 (1990).
Rusche et al., “Antibodies That Inhibit Fusion of Human Immunodeficiency Virus-infected Cells Bind a 24-amino Acid Sequence of the Viral Envelope, gp120,”Proc. Natl. Acad. Sci. USA85:3198-3202 (1988).
Salk et al., “Control of Influenza and Poliomyelitis with Killed Virus Vaccines,”Science195:834-847 (1977).
Salk, Jonas, “Prospects for the Control of AIDS by Immunizing Seropositive Individuals,”Nature327:473-476 (1987).
Stephens et al., “A chink in HIV's armour?”Nature343:219 (1990).
Vandenbark et al., “Immunization with a Synthetic T-cell Receptor V-region Peptide Protects Against Experimental Autoimmune Encephalomyelitis,”Nature341:541-544 (1989).
Van Eendenburg et al., “Cell-Mediated Immune Proliferative Responses to HIV-1 of Chimpanzees Vaccinated With Different Vaccinia Re

Affiliated with

Also associated with

Rating

HIV env antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV env antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV env antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3616546